E
Mangoceuticals, Inc. MGRX
$2.49 -$0.08-3.11% NASDAQ
Recommendation
Prev Close
$2.57
Volume
200,426
Avg Vol (90D)
143,471
Market Cap
$13.28M
Dividend & Yield
--
52-Week Range
$1.49 - $16.80
P/E (TTM)
--
EPS (TTM)
-$5.00
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Short Interest in Mangoceuticals, Inc. (NASDAQ:MGRX) Rises By 237.3%
4/17/2025 - Ticker Report
Mangoceuticals Issues Bonus Shares to Leadership
4/11/2025 - TipRanks Financial Blog
Mangoceuticals enters master distribution agreement for Diabetinol rights
3/25/2025 - The Fly
Mangoceuticals Expands into $33 Billion Addressable Diabetes Market Through its Exclusive Rights to Market and Sell Patented and Clinically Proven Diabetinol in the USA and Canada
3/25/2025 - Globe Newswire
Mangoceuticals launches PeachesRx women's telehealth brand
2/20/2025 - The Fly
Mangoceuticals Announces the Launch of PeachesRx - a Women's Telehealth Brand Focused on Personalized Wellness and GLP-1 Weight Loss Treatments
2/20/2025 - Globe Newswire
Mangoceuticals advances research on patented respiratory illness technology
2/12/2025 - The Fly
Mangoceuticals Advances Antiviral Research on its Patented Respiratory Illness Prevention Technology With New Study Targeting Avian Flu in Poultry Using a Non-Invasive, Non-Pharmaceutical Water-Based Solution
2/12/2025 - Globe Newswire
Mangoceuticals Expands COO Role and Increases Compensation
2/7/2025 - TipRanks Financial Blog
Mangoceuticals advances H1N1 study conducted by Vipragen
2/6/2025 - TipRanks Financial Blog
Mangoceuticals advances H1N1 study conducted by Vipragen
2/6/2025 - The Fly
Mangoceuticals Advances H1N1 Efficacy Study Noting Significant Reduction in Viral Load in Phase ...
2/6/2025 - GuruFocus
Mangoceuticals Advances H1N1 Efficacy Study Noting Significant Reduction in Viral Load in Phase 1 Studies and Engages Vipragen Biosciences to Structure H5N1 Cohort for Expanded Research
2/6/2025 - Globe Newswire
Mangoceuticals executes exclusive distribution agreement with Propre
2/3/2025 - The Fly
Mangoceuticals, Inc. Executes Exclusive Distribution Agreement with Propre Energie for Clinically Proven Dermytol Skincare Treatment Targeting Hyperpigmentation
2/3/2025 - Globe Newswire
Mangoceuticals (NASDAQ:MGRX) Enters into Securities Purchase Agreements with Institutional Investors
1/11/2025 - Ticker Report
Mangoceuticals (NASDAQ:MGRX) Enters into Securities Purchase Agreements with Institutional Accredited Investors
12/27/2024 - Ticker Report
Mangoceuticals, Inc. Completes Acquisition of Mushroom-Based Wellness and Innovations Patent
12/19/2024 - GuruFocus
Mangoceuticals, Inc. Completes Acquisition of Mushroom-Based Wellness and Innovations Patent
12/19/2024 - GuruFocus
Mangoceuticals, Inc. Completes Acquisition of Mushroom-Based Wellness and Innovations Patent
12/19/2024 - Globe Newswire
Mangoceuticals initiates investigation into potential stock manipulation
12/4/2024 - TipRanks Financial Blog
Mangoceuticals initiates investigation into potential stock manipulation
12/4/2024 - The Fly
Mangoceuticals, Inc. Initiates Investigation into Potential Stock Manipulation Scheme Following ...
12/4/2024 - GuruFocus
Mangoceuticals, Inc. Initiates Investigation into Potential Stock Manipulation Scheme Following Recent Reverse Stock Split
12/4/2024 - Globe Newswire
Income Statement
Total Revenue (TTM)
$615.90K
EBITDA (TTM)
-$7.37M
EBIT (TTM)
-$8.11M
Net Income (TTM)
-$8.71M
Balance Sheet
Total Assets (Q)
$15.37M
Total Debt (Q)
$215.00K
Total Liabilities (Q)
$1.43M
Book Value Per Share (Q)
$4.30
Cash Flow
Cash from Operations (TTM)
-$4.86M
Cash from Investing (TTM)
$65.00K
Cash from Financing (TTM)
$4.13M
Net Change in Cash (TTM)
-$680.40K
Filings
Filing Date
Thursday, March 20, 2025
Period Date
Tuesday, December 31, 2024
Next Filing
Week of May 12 and 16 (est)
Price History
Loading...
Beta
-0.25
7-Day Total Return
42.29%
30-Day Total Return
-52.84%
60-Day Total Return
-13.24%
90-Day Total Return
-1.97%
Year to Date Total Return
0.00%
1-Year Total Return
-44.65%
2-Year Total Return
-81.56%
3-Year Total Return
--
5-Year Total Return
--
52-week Low
Apr 11, 2025 - $1.49
52-week High
May 21, 2024 - $16.80
Valuation
Market Cap
$13.28M - Nano Cap
Enterprise Value
$13.44M
Price/Sales (TTM)
10.94
Price/Book (Q)
0.60
Dividends and Shares
Shares Outstanding
2.62M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.mangoceuticals.com
Phone Number
214 242 9619
Address
15110 North Dallas Parkway
Dallas, TX 75248
Country
United States
Year Founded
2021
Business Description
Sector
Consumer Staples
Industry
Consumer Staples Distribution and Retail
Mangoceuticals, Inc. engages in the development, marketing, and sale of various men’s wellness products and services through a telemedicine platform in the United States. It offers erectile... more
NASDAQ 04/21/2025 4:00PM Eastern Quotes delayed